ABSTRACT
We have recently shown that it is not possible to restore euthyroidism completely in all tissues ofthyroidectomized rats infused with T, alone. The present study was undertaken to determine whether this is achieved when T, is added to the continuous SC infusion of T,. Thyroidectomized rats were infused with placebo or T, (0.80 and 0.90 wg/lOO g BW.day), alone or in combination with T, (0.10,0.15, or 0.20 pg/lOO g BW.day).
Placebo-infused intact rats served as euthyroid controls.
Plasma and 12 tissues were obtained after 12 days of infusion.
Plasma TSH and plasma and tissue T, and T, were determined by RIA. Iodothyronine deiodinase activities were assayed using cerebral cortex, pituitary, brown adipose tissue, liver, and lung. Circulating and tissue T, levels were normal in all the groups infused with thyroid hormones.
On the contrary, T, in plasma and most tissues and plasma TSH only reached normal levels when T, was added to the T, infusion.
The combination of 0.9 pg T, and 0.15 Fg T,/lOO g BW.day resulted in normal T, and T, concentrations in plasma and all tissues as well as normal circulating TSH and normal or near-normal 5'-deiodinase activities. Combined replacement therapy with T, and T, (in proportions similar to those secreted by the normal rat thyroid) completely restored euthyroidism in thyroidectomized rats at much lower doses of T, than those needed to normalize T, in most tissues when T, alone was used. If pertinent to man, these results might well justify a change in the current therapy for hypothyroidism.
(Endo&nology 137: 2490-2502, 1996) T 4 IS WIDELY used for the replacement therapy of hypothyroidism in humans. Although thyroidal T, secretion is deficient in these patients, the current hypothesis is that peripheral conversion of the orally administered T4 to T, in tissues is able to provide normal circulating and tissue concentrations of T, and would thus be able to ensure euthyroidism.
The latter presumably would require normalization of both T, and T, (or at least TX) in tissues (1). Attainment of euthyroidism is usually assessed on the basis of normalization of circulating TSH (2), which is actually only measuring the thyroid hormone status of the hypothalamus and thyrotrophs. It is implicitly admitted that to attain euthyroidism in hypothyroid patients with T, alone, it might be necessary to maintain circulating TJ concentrations in the upper limits of the normal range (3). Indeed, circulating T, concentrations are higher in hypothyroid patients on T, than in normal individuals with similar concentrations of plasma T, and TSH (4). On the contrary, plasma T, concentra-tions in patients receiving T, treatment with normal plasma TJ and TSH concentrations are only 80% of those in normal individuals (3).
We recently confirmed (1) in thyroidectomized rats receiving replacement therapy with T, alone that the dose of T, needed to normalize circulating T, and TSH levels results in supraphysiological concentrations of plasma T,. Moreover, the resulting concentrations of T, in the 10 tissues studied is clearly higher than the normal range. Despite this, T, concentrations did not reach normal values in some tissues. Finally, the dose of T, needed to ensure a normal T, concentration (and, presumably, euthyroidism) is not the same for all tissues. It was evident that even if the undesirable effects of excessive T, concentrations were disregarded, peripheral conversion of T, to T, did not fully compensate for the absence of thyroidal secretion of T,. Using thyroidectomized rats infused only with T, in doses ranging from 0.25-2.0 pg/lOO g BWeday, it was not possible to normalize T, concentrations simultaneously in plasma and all tissues (5). In the present study we compared the effects of infusion of T, alone with the effects of infusion of several combinations of T, plus T,. As will be seen, T, must be added to T, to completely restore normal tissue concentrations of both T, and T, in thyroidectomized rats. The combination of 0.90 pg T, and 0.15 pg TX/100 g BWeday was that which resulted in normal thyroid hormone concentrations in plasma and the 12 tissues studied as well as normal plasma TSH levels and normal or near-normal activities of 5'-iodothyronine deiodinase (5'D) in pituitary, liver, lung, cerebral cortex, and brown adipose tissue (BAT). This corresponds to a molar ratio of T, to T, similar to that reported by others (6-10) for the daily thyroidal production of T, and T, in normal adult rats. The addition of these small amounts of T, to the infusion allowed a significant reduction in the dose of T, needed to normalize T, in the majority of tissues with respect to the dose needed when T, alone is infused and avoided supraphysiological T, concentrations.
Materials and Methods

Experimental design
Young female Wistar rats, 120-150 g BW, were surgically thyroidectomized and received 100 FCi i3iI, ip, 1 week later. After 28 days, rats with complete body weight stasis were divided into groups of six rats each, and osmotic minipumps (model 2ML2, Alzet Corp., Palo Alto, CA) were implanted under the dorsa! skin of the animals. Rats were infused with either placebo solution or T, at doses of 0.80 and 0.90 pg/lOO g BW.day, alone or in combination with T, at doses of 0.10, 0.15 and 0.20 pg/lOO g BW.day. The doses of T, were selected on the basis of results obtained in a previous study by our group (l), in which doses ranging from 0.6-1.0 pg/ 100 g BW.day tended to normalize plasma and tissue T, concentrations, whereas higher doses resulted in elevated T, concentrations in plasma and most tissues. The doses of T, that were added to the T, infused into the rats were selected as to cover a wide range of T, to T, molar ratios, from 3.6:1 to 7.6:1. One group of seven nonthyroidectomized rats, matched for sex and age and infused with placebo, served as the control euthyroid group. After 12 days of infusion, the rats were slightly anesthetized with ether, bled extensively from the abdominal aorta after injection of a small amount (30-50 ~1) of heparin (0.17% in 0.9% NaCI), and perfused with 50 ml PBS (0.05 M phosphate buffer containing 0.9% NaCl, pH 7.4). Samples of plasma (PI), cerebral cortex (Cx), cerebellum (Cb), pituitary (I'), BAT, heart (H), liver (L), lung (Lu), spleen (S), kidney (K), ovary (0), adrenal (A), and skeletal muscle (musculus quadriceps femoris; M), were obtained.
Samples were immediately frozen on dry ice and stored at ~20 C until analyzed, with the exception of aliquots of Cx, BAT, L, and Lu, which were stored at ~80 C for measurement of iodothyronine deiodinase activity.
Determinations
T, and T, were measured in whole plasma by specific and highly sensitive RIAs, as previously described (ll), and in tissues after extraction and purification of the iodothyronines, as detailed previously (12, 13). In brief, methanol is added to the still frozen tissue sample and homogenized.
This avoids postmortem generation of T, from T, and degradation of T, or T, (13). 
Results
The absolute values of plasma T,, T,, and TSH; tissue T, and T,; and 5'D-I and 5'D-II are shown in Tables 1, 2A and 2B. The statistically significant differences with respect to normal intact control rats infused with placebo are schematically summarized in Tables 3 and 4 . To facilitate the comparisons between different tissues, the results are represented in the figures as percentages of the mean value for the control group of intact rats.
Circulating
and tissue T4 and T.? and plasma TSH concentrations Plasma T, concentrations were within the normal range in all groups infused with T,, either alone or in combination with T,, and low in the thyroidectomized rats infused only with placebo (Table 3 and Fig. 1A ). Plasma T, was very low in the group infused with placebo, moderately low in the groups infused with T, alone, and normal in the groups infused with combinations of T, and T, (Table 3 and Fig. 1A ). Plasma TSH levels were very high in the thyroidectomized rats infused with placebo and remained elevated when T, was infused alone or in combination with the smaller doses of T,. It reached normal levels only in the groups infused with the combinations of 0.8 pg T, plus 0.20 pg T,/lOO g BW*day, 0.9 pg T, plus 0.15 PLg T3/ 100 g BWmday, and 0.9 pg T, plus 0.20 wg T,/lOO g BWeday (Table 3 and Fig. 1B) .
The changes in tissue T, and T, were similar to those described for the circulating concentrations of iodothyronines. As a rule, T, reached normal or near-normal concentrations in all tissues of the groups infused with T,, whether alone or in combination with T, (Table 3 and Figs. 2 and 3 ). On the contrary, T, levels were low in most tissues when T, was infused alone, although they were significantly higher than those in placebo-infused thyroidectomized rats. The addition of T, in the doses used here was effective in normalizing tissue T, concentrations (Table 3 and Figs. 2 and 3 ). The combination of 0.9 pg T, and 0.15 pg T3/ 100 g BW*day was especially effective, as it resulted in normal levels of plasma T,, T,, and TSH, and normal concentrations of T, and T, in all the tissues studied (Table 3) . Although T, concentrations only became normal in most tissues when the infusion of T, was combined with that of T,, in the case of Cx, BAT, Cb, and A, normal T, levels were also reached with T, alone with the dose of 0.8 pg or 0.9 mg T,/lOO g BW*day, or both (Table 3 and Fig. 2 ). This observation confirms the previous results (I) that, in contrast with other tissues, normal concentrations of T, in Cx, Cb, and BAT are reached even with the relatively low T, doses used here regardless of whether T, is also infused. The molar T, to T, ratios in plasma and tissues are summarized in Table   5A and 58. The combinations leading to normalization of the T, to T, ratios in the majority of tissues were 0.8 PLg T, and 0.15 PLg TX/ 100 g BWeday, and 0.9 Fg T, and 0.15 pg T3/ 100 g BWaday. The latter would appear to be the combination of choice, when normalization of circulating TSH and of T, and T, in plasma and all tissues are also taken into consideration (Table 3 ). Visual inspection of Figs. 1-3 shows that the pattern of changes in the concentrations of T, in all of the tissues studied resembles that observed for circulating T,. The pattern of changes observed for T, concentrations in many tissues resembles that observed for circulating T,, with the exception of Cx, Cb, and BAT, for which the changes were more similar to those in plasma T,.
Type I and II 5'D activities in several tissues
The 5'D activities of several tissues are summarized in Table 4 and Fig. 4 . Cerebral cortex 5'D-II activity was elevated in the group of thyroidectomized rats infused with placebo and normal in all groups infused with T,, either alone or in combination with T,. The 5'D-II activity of BAT was elevated in the group of thyroidectomized rats infused with placebo, normal in the groups infused with T, alone, and variable in the groups infused with T, plus T,. The elevation of BAT 5'D-II activity found in some of the groups infused with combinations of T, and T, grossly paralleled the evolution of BAT T, concentrations (Figs. 2 and 4). Pituitary 5'D-II activity was elevated in thyroidectomized rats infused with placebo and T, alone, and only decreased to normal in the groups infused with 0.8 pg T, plus 0.20 pg T,/lOO g BW*day, 0.9 pg T, plus 0.15 pg T,/lOO g BW*day, and 0.9 pg T, plus 0.20 pg T3/ 100 g BW*day (Table 4 and TSH in the same groups, but no concordance was found with the changes in plasma T, and T, (Table 3 and Fig. 1 ). In contrast, pituitary 5'D-I activity was low in thyroidectomized rats infused with placebo and T, alone, and only became normal in the groups infused with 0.8 PcLg T, plus Tables 3 and 4 . Tables 3 and 4. 0.15 pg T,/lOO g BWeday, 0.8 pg T, plus 0.20 pg T,/lOO g BWeday, and 0.9 wg T, plus 0.20 pg T3/ 100 g BW*day (Table  4 and T,  T:,  TSH  T,  T:,  TSH  T,  T:,  TSH  T,,  T:,  TSH  T,,  T:,  TSH  T,  T:,  TSH  T,  T:,  TSH  T,  T: , TSH Table 3. group infused with 0.8 p.g T, plus 0.10 pg T,/ 100 g BW*day (Tables 3 and 4 and Figs. 1 and 3 ).
Discussion
The experimental design
The aim of a hormonal replacement therapy is to ensure an adequate supply of the missing hormone in a manner that mimics the normal supply as closely as possible and results in normal biological effects, both qualitatively and quantitatively. When the thyroid gland is absent or not capable of synthesizing or secreting T, and T, in humans, treatment with T, alone is preferred over that with T, alone because the former is the main secretory product of the gland and generates T, in many tissues, some of which are a source of systemic T, distributed throughout the body by the bloodstream. However, as thyroidal secretion of T, is still missing when this therapeutic approach is used, combined T, and T, treatment seems to be a more physiological approach. The present experimental design was based on results previously obtained in thyroidectomized rats on replacement therapy with T, or T, alone (1,5). In the rat it is difficult to quantify doses given orally, either in food or drinking water, and we have, therefore, used continuous SC infusion of the iodothyronines as the route of administration of choice. Compared to intermittent ip or iv injections, continuous SC infusion avoids the wide daily fluctuations in the plasma and tissue concentrations of both T, and T, (19), as well as fluctuations in a biological end point of action, such as circulating TSH (20), which have been described with intermittent injections of iodothyronines. Moreover, the use of osmotic minipumps does not require restraint of the animals, thus allowing free access to food and water. The period of infusion in our study was 12 days, which is 17 times the mean residence time of T, in adult rats (17.4 h) (21). Previous studies by others (22, 23) have shown that adult rats receiving a constant infusion of radiolabeled TA are in equilibrium by 6 (euthyroid rats) or 8 (hypothyroid rats) days of infusion, when the amounts of labeled metabolites excreted daily into the feces and urine become constant and their sum is equivalent to the amount of radioactivity infused daily. The corresponding periods are 3 and 8 days, respectively, when labeled T, is infused. In the present study infusion into hypothyroid animals of T,, with or without T,, was, therefore, extended beyond the period when restoration to euthyroidism is accompanied by changes in thyroid hormone metabolism.
Obviously, with this mode of administration diurnal rhythms of circulating T, and T,, which might be dependent on the circadian variations in TSH (24), would be abolished. Those rhythms that are caused by intra- cellular events, such as those described for deiodinase activities in several areas of the rat brain (25) or the pineal gland (26), might, however, still be operative. The two doses of T, used for the present study were selected from the observation (1) that when T, alone is infused, doses ranging from 0.6-1.0 pg/lOO g BW*day tended to normalize plasma and tissue T, concentrations, whereas higher doses resulted in supraphysiological T, concentrations in plasma and most tissues. The doses of T, that were added to the T, infusion were selected so as to cover a wide range of T, to T, molar ratios, from 3.6:1 up to 7.6:1. This ought to include the value of 5.7 2 0.5:1 assessed in five different groups of normal adult male rats (6-9), and the single value of 6.5:1 reported for normal adult female rats (10). Also, all doses of T, tested here were lower than that needed to normalize T, in plasma and most tissues when T, alone was infused (5).
Maintenance of euthyroidism in tissues
Several criteria might be considered for defining euthyroidism, or normal thyroidal status, of a tissue. One criterion might be that the biological effects of thyroid hormones are qualitatively and quantitatively the same as those in tissues from normal animals; another could be that normal concentrations of thyroid hormones are provided to the tissue. The latter criterion assumes that normalization of the iodothyronine content of the tissue would be followed by normalization of the biological effects. It is at present very difficult to apply the first of these two criteria, because of the paucity of biological end point that we can attribute to direct local effects of the thyroid hormones in different tissues. At present, we have to rely on the second criteria for euthyroidism, which encloses two possibilities, namely 1) that both T, and T, have to be normal; or 2) that it is enough to ensure normal T, concentrations to elicit qualitatively and quantitatively normal biological end points. We have shown that using T, or T, alone it is not possible to meet either one of these two possibilities simultaneously for plasma and tissues (1, 5) despite the wide range of doses used for the studies (from 0.2-8.0 PLg T,/lOO g BW*day, and 0.25-2.0 pg T3/ 100 g BW*day). Moreover, when infusing T, alone, supraphysiological T, concentrations have to be reached in most tissues to normalize their T, concentrations, and this occurs at different T, doses for different tissues (1). When using T, alone, T, concentrations in plasma and tissues are always very low, and supraphysiological T, concentrations have to be reached in the circulation to normalize T, levels in many tissues (5). The present data, on the contrary, show that the combined infusion of appropriate amounts of T, plus T, is able to completely restore euthyroidism simultaneously in all tissues of thyroidectomized rats. This demonstration is not only based on the restoration of both T, and T, concentrations in plasma and tissues, but also on the normalization of some of their biological effects, as assessed by plasma TSH levels, and 5'D activities in some tissues.
As assessed from plasma TSH, 1.6 pg T,/ 100 g BW*day are needed to decrease to normal the elevated TSH levels in thyroidectomized rats (1). The T, doses used here (0.8 or 0.9 pLg/ 100 g BW*day are inadequate despite the fact that all of the animals had normal plasma T, levels. In these conditions, the normalization of circulating TSH was clearly related to the dose of T, infused together with T, and the resulting circulating T, levels, in agreement with a previous study by Emerson rt al. (27) .
The addition of the small doses of T, used here decreases the amount of T, (0.8-0.9 pg/lOO g BW*day) needed to normalize T, in the majority of tissues by about 50% compared to the amount (1.6-2.0 pg/lOO g BWoday) necessary when T, alone is used (1). A possible explanation for this finding is that 5'D-I activity, which is low in hypothyroid animals, is regulated by T, (28). As a consequence, when hypothyroid animals are infused with T, alone, plasma T, is low, and doses of 1.6-2 PcLg T,/ 100 g BW*day are needed to normalize it, as most of systemic T, is contributed by tissues with 5'D-I activity. When T, is infused in the doses reported here, 5'D-I activity increases rapidly (5). Addition of T, to a dose of T, thus enhances the formation of T, generated from T, in 5'D-I-containing tissues and, as a consequence, contributes to systemic T, to a greater degree than does the same dose of T, alone. The T, generated from T, would also contribute to a further increase in 5'D-I activity, so that more T, would be generated from the same amount of T,. Because of these mutually potentiating effects, much less T, would be necessary for normal T, levels to be reached in most tissues.
Moreover, with the present approach, T, concentrations are not increased above normal values in any of the tissues studied. This appears desirable, as we do not know whether long term adverse effects might result from chronically elevated intracellular T, concentrations or from permanent stimulation or suppression of iodothyronine deiodinases. With the combination of 0.9 PLg T, and 0.15 Fg T,/lOO g BW*day, overstimulation of TSH secretion and of the compensatory mechanisms needed to convert T, into T, is no longer necessary to ensure euthyroidism in all tissues. Of the different combinations tested in the present study, the most effective in restoring euthyroidism in thyroidectomized rats has been 0.9 pg T, plus 0.15 kg T3/ 100 g BW.day, 
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in which T, and Ts are in a 5.0:1 molar ratio, similar to that present in the normal thyroidal secretion of the rat, which is approximately 5.7 rt 0.5:1, as cited above (6-9).
The amounts of both T, and T, infused daily with the above combination into the thyroidectomized rats of the present study are somewhat higher than values reported for the daily thyroidal production rates in adult rats. The daily T4 production rate, as assessed by isotopic equilibrium with labeled T, infused iv, has been reported to be 0.68 t: 0.23 pg T4/ 100 g BW (range, 0.63-0.76) for male rats (6-9) and 0.73 + 0.05 pg T4/ 100 g BW (range, 0.73-0.87) for females (10,29, T3 dose @g/100 g/day) l T4 0 T3 30). The average value derived by pulse kinetics after iv injection of a single tracer dose of labeled T4 is quite similar (0.75 pg T4/ 100 g BW) (21). There are fewer studies reporting the thyroidal secretion rate of T,, as most studies did not determine the T, secreted by the gland but, rather, the total T, production rate, which also includes T, generated from T, in peripheral tissues. The values reported to date from one laboratory for the daily thyroidal secretion rate are 0.10 2 0.09 pg TJlOO g BW (range, 0.08-0.14) for males (6-9) and 0.09 pg T,/lOO g BW for females (lo), which represent about 37% of the total T3 production (0.28 ?Z 0.01 Fg T3/ 100 g BW). Table 3 . The T,: T, ratio for the placebo-infused thyroidectomized was not calculated, as the concentrations ofboth iodothyronines were very low often, near the detection limits, and small variations could lead to spurious differences. Molar ratios were calculated using a mol wt of 652 g for T, and 777 g for T,. The symbols represent the comparison of the mean values of the groups infused with thyroid hormones with the mean values of the control group; they are explained in Table 3 . The T:JT, ratio for the olacebo-infused thvroidectomized was not calculated. as the concentrations ofboth iodothyronines were very low often, near the detection limits, I " and small variations could lead to spurious differences.
These values have been obtained by the more direct steady state kinetic approach presently available, using the simultaneous infusion of T, and T, labeled with different isotopes. These results and our present ones contrast with a recent report (31) which concluded that the thyroid gland is the major source of circulating T, in the rat. The approach was less direct than the steady state kinetic method indicated above; conclusions were drawn from differences in circulating T, between selenium-supplemented and selenium-deficient rats. The latter have very low hepatic activity of the selenoprotein 5'D-I. We cannot at present explain why the daily doses of both T, and T, that we must infuse to ensure euthyroidism in all tissues are higher than these calculated thyroidal production rates. There are many possible differences between laboratories, such as strain and age of the animals used, or foodrelated differences in fecal loss of the iodothyronines.
Moreover, the route of infusion has been different (SC in our experiments US. iv in others), and this might result in different degrees of absorption of the infused doses. It is also possible that the difference is related to the fact that our choice of the combination of 0.9 kg T, plus 0.15 PLg TX/100 g BW*day as adequate to compensate for the absence of thyroidal secretion is based on data obtained in plasma and 12 different tissues as well as on several biological effects, whereas the calculated production rates summarized above have been derived exclusively from plasma iodothyronine concentration data.
Compensatory mechanisms
The present combined T, plus T, replacement therapy with 0.9 PLg of T, plus 0.15 pg TX/100 g BW*day results in normalization or near-normalization of compensatory mechanisms, such as changes in circulating TSH and 5'D activities, operating in the placebo-infused thyroidectomized rats. The addition of T, to the T, dose should not prevent a normal response of these mechanisms when increased plasma and tissue T, concentrations are needed to meet higher demands. However, it might be argued that the addition of T, to the T, LUNG infusion dose would impair the adaptation to decreased denonthyroidal illness as is the decreased deiodination of T, to mands for T,. This might be the case for a hypothyroid Ta (32,34). As evidenced here by the increase in plasma and animal receiving thyroid hormone replacement therapy tissue T3 concentrations in the rats infused with T, alone faced with conditions, such as food restriction or nonthycompared to levels in rats receiving a placebo infusion, an roidal illnesses, in which a decreased concentration in tissues important part of the T, found in rats receiving the combined is considered a life-saving or protective response (32, 33) . The infusion is derived from the conversion of T, to T,, and this decreased release of TRH from the hypothalamus followed fraction should still be under metabolic control even if T, is by decreased plasma TSH and decreased sensitivity of thyadded to the T, infusion. Moreover, in rat models of nonrotrophs to TRH and, consequently, a decrease in the thythyroidal illness, such as streptozotocin-induced diabetes roidal secretion of T, and T, is as typical a response to severe and food restriction, the daily production of T3 from T, is have to be markedly reduced to solve the problem posed by severe nonthyroidal illness in hypothyroid patients receiving replacement therapy, and that the mere withdrawal of T, from the replacement therapy would have a relatively minor effect. In any case, if replacement therapy has to be adjusted during the illness, the patient could be given T, alone.
Possible clinical implications
The aim of substitution therapy for hypothyroidism in humans is to replace the thyroidal secretion of thyroid hormones. The widely accepted approach to this treatment is the oral administration of T, alone (Z), for reasons summarized in the introduction.
This treatment might not be the most appropriate in view of our recent (1) and present results in thyroidectomized rats, which show that combined therapy with T, plus T, is a more physiological approach. Secretion of T, by the normal human thyroid gland represents a smaller proportion of the total secretion of hormone than that in the rat; the reported T, to T, molar ratios are 14:l for man (35) and 5.7:1 for the rat (6-9). This suggests that T, concentrations in human extrathyroidal tissues might be affected to a lesser extent than those in the rat by changes in the amount of T, secreted by the gland. Moreover, in patients, some residual functioning thyroid tissue may be present, and secretion of T, may be preferentially preserved over that of T, (36). However, any remnant thyroid function would be substantially reduced once TSH levels became normal with T, therapy. Despite these differences between the present experimental model and the situation encountered in clinical practice, there are similarities which suggest that patients might also benefit from an approach comparable to that used here. The scarce data available from a mixed population of hypothyroid patients receiving oral T, replacement therapy indicate that for similar concentrations of plasma T, and TSH, circulating levels of T, are elevated compared to those in matched controls (4). Our results in rats (I) suggest that the same might apply for their tissues. If so, the addition of small proportions of T, to the replacement therapy with T, might improve simultaneous attainment of euthyroidism in all tissues and avoid high T, concentrations and the chronic overstimulation of compensatory mechanisms. For years, the suggested dose for replacement therapy in hypothyroid patients was 200-400 PLg T,, administered orally (37). At present, however, with the advent of highly sensitive plasma TSH assays and improved evaluation of the potency of T, preparations (38) , the recommended dose has been reduced to 100-150 pg/day (2). Approximately 80% of the orally administered T, is absorbed (4); therefore, this replacement dose is not very different from the thyroidal T, secretion rate for a normal adult. Pilo et al. (35) assessed the mean daily thyroidal production rate of T, and T, by simultaneously injecting T, and T,, labeled with different isotopes. To our knowledge, this is the only study in humans in which the thyroidal secretion of T, can be evaluated; in most other studies (21), only the total body production rate of T, can be calculated. The study was performed in a group of 14 normal adults from an area with a normal iodine intake, which included both men and women between 19-65 yr of age with a mean body wt and surface area of 70 kg and 1.79 m2, respectively.
The mean daily thyroidal production of T, is 56.2 pg/m2, corresponding to 101 kg T,, a value in agreement with previous assessments (21) of the T, production rate (96 pg/day) in man. The thyroidal production rate of T, is 3.3 pg/m2, which corresponds to an average of 6 pg T,. This amount of T, is approximately one fourth of the total T, production rate (thyroidal secretion plus extrathyroidal generation from T,) of 26 pg TX/day. According to these estimates, the total thyroidal production of thyroid hormones in man would be 101 pg T, and 6 PLg T,.
The relatively small difference between the replacement dose of T, usually administered and the thyroidal secretion rate appears to contrast with present results. The preferred doses of T, and T, infused SC into thyroidectomized rats are higher than the reported thyroidal secretion rates for normal animals, and the amount of T, infused to ensure normal T, levels for the majority of tissues is decreased almost 50% by concomitant addition of a small amount of T,. In this respect, however, we should like to point out that the criteria for defining the adequate dose are also different. The T, dose is usually adjusted to the individual patient on the basis of achievement of normal circulating TSH and T, levels (36), because subtle changes in the feeling of well-being of the patient are more difficult to quantify. In the experimental studies, the preferred dose also takes into account the concentrations of T, and T, in tissues as well as some biological end points. If such results (1) are pertinent to man, restoration to normal of plasma T, and TSH levels, even in the presence of supraphysiological plasma T, concentrations, might not ensure normal T, concentrations in all tissues, and the doses of T, presently used might be inadequate to attain euthyroidism in some tissues.
It would appear that thyroid hormone substitution therapy in a hypothyroid patient ought to ensure that the amounts of T, and T, continuously absorbed into the bloodstream are at least equivalent to the corresponding thyroid secretion, namely approximately 100 PLg T, and 6 PLg T, / day. The actual amounts that would have to be administered to achieve this are likely to be higher, depending on the route of administration and the degree of absorption of the iodothyronines. It should be possible to adjust treatment using simultaneous normalization of circulating T,, TSH, and T, as a guideline. Although at present, therapy with T, alone is preferred (2,3, 36,39), the daily oral administration of combinations of T, and T, has already been used for treatment of hypothyroid patients, but was largely abandoned, because it was associated with several problems related to 1) wide fluctuations in circulating T, concentrations and, possibly, 2) the addition of an excessive amount of T, to the daily Tj dose. Such problems have been avoided in the present experiment by the use of continuous delivery and combinations of T, and T, in relative proportions resembling those normally secreted by the gland. 1) The mean residence time of T, in man is 310 h (13 days) (21). Treatment with a daily dose of T, means that 13 doses are given during this period, and fluctuations in circulating T, are likely to be buffered. Delivery of T, into the bloodstream would be relatively comparable to the delivery of T, by the continuous SC infusion used by us. On the contrary, the mean residence time of T, in man has been calculated to be 59.3 h (2.5 days) (21). If the T, supplement were given once daily, only 2.5 doses would be administered during the mean residence period. This is quite different from the continuous delivery by constant infusion used for the present study and is likely to lead to the much wider and more frequent fluctuations in circulating T, concentrations compared to those of T, administered once daily, which have been described in hypothyroid patients receiving oral T, plus T, combination replacement therapy (34). The route of administration may also play a role, as the intestinal absorption of T, is faster than that of T,, further contributing to the appearance of peaks of elevated plasma T, (40). The amount of T, reaching tissues might well be excessive during part of the interval between the daily doses and lead to undesirable thyroid hormone effects, especially in those tissues deriving most of their T, supply directly from plasma, such as the heart (23).
2) The preparations used for combined therapy with T, plus T,, such as Liotrix (in the U.S.), Diotroxin (Glaxo Laboratories, Madrid, Spain), and Novothyral (Merck Laboratories, Darmstadt, Germany), probably contained an excess of T, compared to T,; the molar ratios of T, to T, were 3.4:1 (4:l by wt), 7.6:1 (9:l by wt), and 4.2:1 (5:l by wt), respectively, whereas the molar ratio for secretion by the human thyroid is 14:l (35). Liotrix [Euthyroid, Parke-Davis Laboratories (Detroit, MI) and Thyrolar, Armour Laboratories (Kankakee, IL)] was available in several formulations with a wide range of doses, which contained from 12.5 PLg T, plus 3.1 PcLg T, to 180 pg T, plus 45 pg T, (Euthyraid3) (41). Diotroxin contained 90 pg T, plus 10 kg T, (42), and Novothyral contained 100 pg T, plus 20 p.g T,. The higher intestinal absorption rate of T, (-90%) (38) compared to that of T, (-80%) (4) would further contribute to the relative excess of T,. Thus, the human daily thyroidal production rate of 101 wg T, and 6 kg T, cited above (35) would not be mimicked with any of these combinations. If more extensive studies in hypothyroid patients support our tentative conclusion that therapy with a combination of T, and T, might be better than substitution with T, alone, the problems previously encountered should be solved. First, assuming similar absorption rates of T, and T,, the preparation should contain T, and T, in a molar proportion of approximately 14:l and deliver into the bloodstream 101 pg T, and 6 PcLg TX/day, thus mimicking human thyroid secretion (35). Second, the route of administration should warrant a constant steady supply of both iodothyronines.
This might be achieved by combining the oral administration of T, with that of sustained enteric release forms of T,, also given orally. Other possible approaches might involve implantation of im preparations with sustained release of T, and T, or the transdermal delivery of both iodothyronines. 
